Availability of comparative real-world evidence research in Medicare patients: implications for Centers for Medicare and Medicaid Services drug price negotiations

Conclusion: Our results demonstrate there is a considerable amount of comparative RWE for apixaban, rivaroxaban, and etanercept but limited comparative RWE for the other drugs set to undergo CMS price negotiations in 2026; additionally, our findings set up a number of next steps (e.g., risk of bias assessments) for further exploration of the available evidence base. Overall, CMS and manufacturers should consider proactively generating high-quality comparative RWE studies in the Medicare population to ensure that future price negotiations are based on robust evidence.PMID:37815792 | DOI:10.57264/cer-2023-0125

Source: Journal of Comparative Effectiveness Research - October 10, 2023 Category: General Medicine Authors: Ashley Jaksa Patrick J Arena Nicolle Gatto Source Type: research